- Home
- ANVS vs TPST Comparison
ANVS vs TPST Comparison
Compare ANVS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- TPST
- Stock Information
- Founded
- ANVS 2008
- TPST 2011
- Country
- ANVS United States
- TPST United States
- Employees
- ANVS N/A
- TPST N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- TPST Health Care
- Exchange
- ANVS Nasdaq
- TPST Nasdaq
- Market Cap
- ANVS 46.1M
- TPST 45.5M
- IPO Year
- ANVS 2020
- TPST N/A
- Fundamental
- Price
- ANVS $2.05
- TPST $10.45
- Analyst Decision
- ANVS Strong Buy
- TPST Hold
- Analyst Count
- ANVS 4
- TPST 3
- Target Price
- ANVS $17.33
- TPST $30.00
- AVG Volume (30 Days)
- ANVS 1.3M
- TPST 47.7K
- Earning Date
- ANVS 11-12-2025
- TPST 11-11-2025
- Dividend Yield
- ANVS N/A
- TPST N/A
- EPS Growth
- ANVS N/A
- TPST N/A
- EPS
- ANVS N/A
- TPST N/A
- Revenue
- ANVS N/A
- TPST N/A
- Revenue This Year
- ANVS N/A
- TPST N/A
- Revenue Next Year
- ANVS N/A
- TPST N/A
- P/E Ratio
- ANVS N/A
- TPST N/A
- Revenue Growth
- ANVS N/A
- TPST N/A
- 52 Week Low
- ANVS $1.11
- TPST $5.35
- 52 Week High
- ANVS $10.54
- TPST $15.73
- Technical
- Relative Strength Index (RSI)
- ANVS 47.27
- TPST 49.98
- Support Level
- ANVS $1.97
- TPST $10.09
- Resistance Level
- ANVS $2.23
- TPST $10.79
- Average True Range (ATR)
- ANVS 0.18
- TPST 0.68
- MACD
- ANVS 0.02
- TPST -0.11
- Stochastic Oscillator
- ANVS 45.15
- TPST 16.93
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.